Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs Evaluating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Possible Risk of NAION Side Effects (Posted by Tom Lamb at Drug Injury Watch) The FDA has been investigating "potential signals" of non-arteritic anterior ischemic optic neuropathy (NAION) with the glucagon-like peptide-1 (GLP-1) receptor agonist class of drugs. For example, NAION with Mounjaro, Zepbound, Wegovy, Rybelsus, and Ozempic. From "October - December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)", here is a full list of the glucagon-like peptide-1 (GLP-1) receptor agonists, or GLP-1 RAs, that are being evaluated: Adlyxin (lixisenatide) injection Bydureon (exenatide) for extended-release injectable suspension Bydureon BCise (exenatide extended-release) injectable suspension Byetta (exenatide) injection Mounjaro (tirzepatide) injection Ozempic (semaglutide) injection Rybelsus (semaglutide) tablets Saxenda (liraglutide) injection Soliqua 100/33 (insulin glargine and lixisenatide) injection Trulicity (dulaglutide) injection Victoza (liraglutide) injection Wegovy (semaglutide) injection Xultophy 100/3.6 (insulin degludec and liraglutide) injection Zepbound (tirzepatide) injection In early June 2025, the European Medicines Agency (EMA) confirmed the link between the semaglutide-containing drugs Wegovy, Rybelsus, and Ozempic and NAION (non-arteritic anterior ischemic optic neuropathy). This drug regulator went on to say a NAION warning would be added to the drug labels for Wegovy, Rybelsus, and...
https://www.drug-injury.com/dr....uginjurycom/2025/06/